期刊文献+

人蛋白激酶CβⅡ基因开放读码框的克隆及序列分析 被引量:3

Cloning and sequencing analysis of human PKCβⅡgene ORF
下载PDF
导出
摘要 目的:克隆人蛋白激酶CβⅡ基因(PRKCB1)的开放读码框(Open reading frame,ORF),为其进一步的功能研究提供基础。方法:采用逆转录-巢式PCR法,从人脐静脉内皮细胞株中扩增出含PRKCB1基因ORF全长的片段,所得片段经加"A"处理并插入T载体。经蓝白筛选,用特异引物扩增阳性重组子,得到编码人蛋白激酶CβⅡ(Protein kinase CβⅡ,PKCβⅡ)基因的ORF,并与T载体相连,测序鉴定。结果:通过巢式RT-PCR及T/A克隆获取了PRKCB1基因的ORF,测序结果与GenBank报道序列一致。结论:成功克隆了PRKCB1基因的ORF,在技术路线上可以为某些难克隆的基因提供参考。 Objective:To clone human PRKCB1 gene open reading frame(ORF) in order to further research on it's function. Methods:RT-nested PCR method was adopted to the amplify the total length of human PRKCB10RF from human umbilical vein endothelial cell (HUVEC).T vector was inserted into the harvested fragment after a tail was added. With blue white screening,the gene ORF encoding human PKCβⅡ was obtained by special primers amplifying recombinant plasmids,and linked into T vector.Then the plasmid was identified by sequencing. Results:The human PRKCB1 ORF was amplified successfully with RT-nested PCR and T/A cloning,and the gene sequence was completely consistent with that reported in GenBank. Conclusion:Human PRKCB1 gene ORF was successfully cloned. The strategy of cloning may provide technical references for some genes hard to be cloned.
出处 《重庆医科大学学报》 CAS CSCD 2008年第1期18-21,共4页 Journal of Chongqing Medical University
基金 国家自然科学基金资助项目(30570877)
关键词 鹰白激酶Cβ基因 聚合酶链反应 T/A克隆 序列分析 PKCβ gene PCR T/A cloning Sequence analysis
  • 相关文献

参考文献11

  • 1Brownlee M. The pathobiology of diabetic complications:a unifying mechanism[J]. Diabetes, 2005 ; 54(6) : 1615-1625.
  • 2Sheetz MJ,King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications[J]. JAMA, 2002 ; 255 (20) : 2579-2555.
  • 3Wakasaki H, Koya D,Schoen FJ,et al. Targeted overexpression of protein kinase C β Ⅱ isoform in myocardium causes cardiomyopathy[J]. Med Sciences,1997;94(17):9320-9325.
  • 4Bosch RR,Bazuine M,Span PN,et al.Regulation of GLUTI-mediated glucose uptake by PKC λ -PKC β Ⅱ interactions in 3T3-L1 adipocytes[J]. Biochem J,2004;384(Pt 2):349-355.
  • 5Francke U,Harper JF, Darras BT,et al.Assignment of human genes for phosphorylase kinase subunits alpha(PHKA) to Xq12-q13 and beta(PHKB) to 16q12-q13[J]. Am J Hum Genet, 1989;45(2): 276-282.
  • 6Kawakami T,Kawakami Y,Kitaura J. Protein kinase C beta (PKC beta) : normal functions and diseases[J]. Biochem J, 2002; 132 ( 5 ) : 677-682.
  • 7Greenham J,Adams M,Doggett N,et al. Elucidation of the exon-intron structure and size of the human protein kinase C beta gene (PRKCB)[J]. Hum Genet, 1995; 103(4) :453-457.
  • 8Idris I,Gray S,Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes[J]. Diabetologia, 2001 ; 44(6) : 659-673.
  • 9Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature, 2001 ; 414(6 865): 813-820.
  • 10Kunisaki M, Bursell SE, Clermont AC,et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway[J]. Am J Physiol,1995;269 (2 Pt 1 ) : E239-246.

同被引文献27

  • 1Avignon A, Sultan A. PKC-inhibition: a new therapeutic approach for diabetic complications [ J ]. Diabetes Metab,2006,32(3) :205 -213.
  • 2Idris I, Donnelly R. Protein kinase C beta inhibition:A novel therapeutic strategy for diabetic microangiopathy [ J ]. Diab Vase Dis Res,2006, (3) :172 -178.
  • 3Casellini CM,Barlow PM,Rice AL,et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy [ J ]. Diabetes Care, 2007,30 (4) : 896 - 902.
  • 4Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes [ J ]. Diabetes Care ,2007,30 (4) :995 - 996.
  • 5PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial [ J]. Arch Ophthalmol,2007,125(3 ) :318 - 324.
  • 6Francke U, Harper JF, Darras BT, et al. Assignment of hu- man genes for phosphorylase kinase subunits alpha (PHKA) to Xq12-q13 and beta (PHKB) to 16q12-q13[J]. Am J Hum Genet,1989,45(2) :276 -282.
  • 7Verrier E, Wang L, Wadham C ,et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway:role of diacylglycerol kinase [ J ]. Circ Res, 2004,94 ( 11 ) : 1515 - 1522.
  • 8Naruse K, Rask-Madsen C,Takahara N,et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance[J]. Diabetes,2006,55(3) :691 -698.
  • 9Kaiser S, Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells [ J ]. J Vasc Res, 2001,38(2) :133 - 143.
  • 10Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res, 2007,55:498- 510.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部